NCT04027556|CompletedDMC
Loading search results
Sponsor study identifier
interventional
90
1 country
1
Study Start
June 27, 2019
Actual (reported)Primary Completion
August 26, 2020
Actual (reported)Study Completion
February 10, 2022
Actual (reported)This study aims to assess whether the acceptable image quality is achievable using low monoenergetic imaging of dual-energy CT with deep learning-based denoising, and low contrast media dose calculated based on lean body weight for the detection of hepatocellular carcinoma.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
February 10, 2022
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
June 27, 2019
Actual (reported)July 18, 2019
Actual (reported)July 22, 2019
Actual (reported)August 26, 2020
Actual (reported)February 10, 2022
Actual (reported)HCC conspicuity
qualitative scoring for focal lesion depiction on four-point scale (1: worst, 4: excellent, representative value is average score)
6 months after complete enrollment
Image noise
12 months after complete enrollment
Image contrast
12 months after complete enrollment
Overall image quality
6 months after complete enrollment
Lesion detection
12 months after complete enrollment
Hounsfield unit
3 months after complete enrollment
Low CT contrast media dose calculated based on lean body weight and low monoenergetic images of dual-energy CT with deep learning-based denoising
Standard CT contrast media dose calculated based on total body weight and conventional images with full model-based iterative reconstruction
CT contrast media (iobitridol 350mgI/kg) is administrated at a dose of 450mgI/kg based on lean body weight.
CT contrast media (iobitridol 350mgI/kg) is administrated at a dose of 560mgI/kg based on total body weight.
Seoul National University Hospital
Seoul, South Korea
Jeong Min Lee, MD
Seoul National University Hospital
90 participants (actual enrollment reported by the registry).
First Submitted
July 18, 2019
First Posted
July 22, 2019
Study Start
June 27, 2019
Actual (reported)Short-term MRI for Treatment Response Evaluation/Prediction of HCC Treated With TARE
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Primary Completion
August 26, 2020
Actual (reported)Study Completion
February 10, 2022
Actual (reported)Last Updated
May 4, 2022
Record last verified: 2022-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: